ABBV – AbbVie Inc.
Healthcare | Drug Manufacturers - General | Website
Quick Stats
Trend Overview
ABBV is in a well-structured bull trend. All major signals are aligned: positive swing trend, rising momentum over 3 days, a fully aligned moving average stack, a golden cross in place, and trend strength confirmed by ADX at 56.9. This is the type of environment where trend-following strategies carry a structural edge.
The trend is your friend here. As long as momentum strength continues to hold or rise, the path of least resistance remains higher. Manage the trade with a trailing stop rather than a fixed target.
Options Signal Highlight
Latest ABBV Reports
ABBV Price Chart
Technical Trend Analysis
As of 21.08.2026 · Close: $264.96 · ATR14: $2.33
ABBV is in a well-structured bull trend. All major signals are aligned: positive swing trend, rising momentum over 3 days, a fully aligned moving average stack, a golden cross in place, and trend strength confirmed by ADX at 56.9. This is the type of environment where trend-following strategies carry a structural edge.
The trend is your friend here. As long as momentum strength continues to hold or rise, the path of least resistance remains higher. Manage the trade with a trailing stop rather than a fixed target.
| Indicator | Signal | Detail |
|---|---|---|
| Swing Trend | ▲ Long | Primary directional bias |
| Momentum | ▲ Up · 3d | Strength: 0.45 – Rising |
| Trend Strength (ADX) | 56.9 – Strong | ADX38: 21.8 |
| Volatility (HV30) | 25.9% – Calm | HV90: 27.6% | HV180: 26.7% |
| Vola Compression | None | Normal range |
| MA Structure | Golden Cross ✓ | Stack: Fully aligned – bullish stack |
| EMA21 Distance | 4.75 ATR ↑ | EMA21: $250.69 |
| GD200 Extension | 7.3 ATR – Extended | GD20: 2.0 | GD50: 2.9 | GD100: 6.7 |
Monthly Performance History
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 | 4.47 | -0.70 | 7.86 | 11.99 | -6.28 | -4.66 | 9.30 | -5.83 | 5.02 | 5.79 | -1.04 | 9.13 | 50.37 |
| 2014 | -5.29 | 7.52 | 2.62 | -0.04 | 5.27 | 4.23 | -8.00 | 5.34 | 4.88 | 10.89 | 9.41 | -5.31 | 25.89 |
| 2015 | -8.41 | -0.33 | -3.18 | 13.24 | 3.53 | 0.39 | 2.19 | -10.50 | -10.07 | 8.02 | -8.25 | 0.37 | -10.09 |
| 2016 | -4.70 | 0.40 | 1.38 | 6.23 | 2.43 | -1.46 |
T 5.61 |
-4.24 | -1.50 | -11.78 |
T 7.71 |
5.85 | 8.70 |
| 2017 | -2.08 | 1.56 |
T 3.71 |
T 1.40 |
-0.69 | 8.69 | -3.47 |
T 6.99 |
17.82 | -0.15 | 4.85 | 0.40 | 54.96 |
| 2018 | 14.03 | -0.44 | -16.86 | 5.57 |
T -3.07 |
-5.51 | -0.95 | 2.20 | 0.02 |
T -18.05 |
T 17.53 |
-1.57 | -6.32 |
| 2019 |
T -10.02 |
-1.57 |
T 0.61 |
-1.72 | -2.76 | -3.94 | -9.24 | -0.09 |
T 15.78 |
8.63 | 7.31 | 1.74 | -0.77 |
| 2020 | -9.53 |
T 4.14 |
-14.09 |
T 11.96 |
11.87 | 8.25 | -4.27 | -0.18 | -5.04 | -2.34 |
T 18.50 |
2.99 | 19.65 |
| 2021 | -2.78 | 5.32 |
T -0.18 |
T 2.75 |
-1.29 | 0.38 |
T 1.79 |
4.62 | -3.92 | 5.12 | 0.41 | 16.81 | 28.45 |
| 2022 | 1.09 | 7.86 | 9.76 | -9.71 | -0.34 |
T 4.89 |
-6.69 | -4.11 | -3.06 | 5.84 | 9.71 | -0.01 | 19.34 |
| 2023 | -9.01 | 4.98 |
T 2.64 |
-5.80 | -10.25 | 0.97 |
T 10.79 |
-1.06 | 0.58 | -4.77 | -0.06 |
T 8.06 |
-4.56 |
| 2024 | 2.87 | 5.05 | 1.78 | -10.02 | -0.30 |
T 7.07 |
8.78 | 3.48 | -0.11 |
T 3.51 |
-10.13 | -2.24 | 11.19 |
| 2025 |
T 2.49 |
9.93 | -0.93 | -5.42 | -3.74 | -0.73 |
T -0.51 |
7.78 | 9.26 | -10.78 |
T 7.43 |
1.50 | 27.34 |
| 2026 | -2.75 |
T 2.85 |
-7.16 | -1.70 |
T 5.38 |
18.18 | -0.05 |
T 8.10 |
15.55 |
T A T badge marks a Trendchange signal in that month. Hover for entry price.
Trendchange Signal History
The last 10 Trendchange signals for ABBV:
| Date | Entry Price | Days Held | +10d | +20d | +30d | +60d |
|---|---|---|---|---|---|---|
| 19.08.26 | $265.97 | 1d | -0.38% | +0% | +0% | +0% |
| 18.05.26 | $209.41 | 45d | +1.68% | +5.82% | +20.17% | +26.53% |
| 13.02.26 | $231.50 | 17d | +0.25% | -1.94% | -1.94% | +8.7% |
| 18.11.25 | $233.87 | 8d | -4.06% | -2.75% | -2.3% | -2.93% |
| 29.07.25 | $191.22 | 51d | +3.88% | +8.54% | +10.04% | +19.92% |
| 31.01.25 | $183.90 | 65d | +5.19% | +13.66% | +15.15% | +23.37% |
| 06.01.25 | $180.10 | 4d | -1.87% | +5.47% | +0% | +0% |
| 03.10.24 | $195.45 | 9d | +0% | +3.1% | +2.07% | +2.78% |
| 06.06.24 | $168.57 | 41d | +2.11% | -1.55% | +2.22% | +18.35% |
| 07.12.23 | $147.97 | 74d | +2.51% | +9.58% | +11.77% | +32.05% |
Signal Statistics – Historical Edge
Calculated edge for ABBV: 11.86%
| Range | N | 10d | 20d | 30d | 60d | Signal |
|---|---|---|---|---|---|---|
| 15-20% | 1 | +18.76% | +15.51% | +23.39% | +30.99% | Hold |
| 5-7% | 3 | +5.41% | +9.82% | +10.2% | +22.5% | Hold |
| 3-5% | 4 | +4.17% | +6.35% | +6.46% | +13.41% | Hold |
| 1-3% | 6 | +2.36% | +4.63% | +7.99% | +19.07% | Hold |
| 0-1% | 2 | +0.15% | -1.92% | -1.62% | +7.18% | Close |
| -1-0% | 6 | -0.52% | +0.03% | +2.81% | +13.6% | Neg |
| -3-1% | 2 | -1.45% | +2.22% | -0.52% | -4.59% | Neg |
| -5-3% | 6 | -4.07% | -3.28% | -0.95% | -1.1% | Neg |
Signal data as of August 21, 2026
Options Metrics
Gamma Exposure Timeline
Key GEX levels, Max Pain, and unusual activity across weekly and monthly expirations, plotted around the current spot price.
Key GEX levels, Max Pain, Anchor, Ceiling and unusual activity across 14-30 DTE, plotted around the current spot price.
Put and call pins mark strikes where dealer gamma exposure concentrates. The GEX flip strike is where dealer hedging shifts from stabilizing (positive gamma) to amplifying (negative gamma) price moves. Max Pain is the strike where the most options expire worthless. Dashed markers flag unusual options activity. Learn how to use these signals in our options strategy guides →
Strategy Setups – You Decide
Based on current options data, 2 setups match the current conditions. Each strategy has different risk/reward characteristics – the final decision is always yours.
All setups above are personal trade journal observations derived from options flow data. This is not financial advice. The decision to trade, and which strategy to use, is entirely yours.
View full options flow data and historical signals on the Options Flow Analysis Overview →
Valuation
| Metric | Value |
|---|---|
| Market Cap | $440.83 B |
| PE Ratio (TTM) | 70.87 |
| Forward PE | 15.32 |
| PEG Ratio | 0.41 |
| EV/EBITDA | 16.50 |
| Price/Sales | 6.85 |
| Price/Book | -74.27 |
| Beta | 0.28 |
Profitability
| Metric | Value |
|---|---|
| Gross Margin | 72.79% |
| Operating Margin | 40.04% |
| Net Margin | 9.80% |
| ROA | 10.51% |
Dividends
| Metric | Value |
|---|---|
| Annual Dividend | $6.92 |
| Forward Yield | 276.00% |
| Payout Ratio | 190.40% |
| Dividend Date | 2026-08-13 |
Analyst Consensus (28 Analysts)
| Metric | Value |
|---|---|
| Median Target | $280 |
| High Target | $328 |
| Low Target | $200 |
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ETF Holdings
AbbVie Inc. is included in 3 ETFs tracked by StockBotty.